M&A Deal Summary

PTC Therapeutics Acquires Agilis Biotherapeutics

On July 19, 2018, PTC Therapeutics acquired life science company Agilis Biotherapeutics for 200M USD

Acquisition Highlights
  • This is PTC Therapeutics’ 2nd transaction in the Life Science sector.
  • This is PTC Therapeutics’ largest (disclosed) transaction.
  • This is PTC Therapeutics’ 2nd transaction in the United States.
  • This is PTC Therapeutics’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2018-07-19
Target Agilis Biotherapeutics
Sector Life Science
Buyer(s) PTC Therapeutics
Deal Type Add-on Acquisition
Deal Value 200M USD

Target

Agilis Biotherapeutics

Cambridge, Massachusetts, United States
Agilis Biotherapeutics, Inc. is a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). Agilis Biotherapeutics was founded in 2013 and is based in Cambridge, Massachusetts.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

PTC Therapeutics

South Plainfield, New Jersey, United States
Category Company
Founded 1998
Sector Life Science
Employees988
Revenue 938M USD (2023)
DESCRIPTION

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. PTC Therapeutics was founded in 1998 and is based in South Plainfield, New Jersey.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 3
Type (Add-on Acquisition) 1 of 2
State (Massachusetts) 1 of 2
Country (United States) 2 of 3
Year (2018) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-03-16 Emflaza

Deerfield, Illinois, United States

Emflaza is a first treatment approved in the United States for all Duchenne muscular dystrophy (DMD) patients five years and older, regardless of their genetic mutation. DMD is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death due to heart and respiratory failure. Emflaza aligns with PTC's mission to bring therapies to patients who have rare diseases with limited or no treatment options.

Buy $140M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-06 Censa Pharmaceuticals

Wellesley, Massachusetts, United States

Censa Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth. Censa Pharmaceuticals is based in Wellesley, Massachusetts.

Buy $10M
Mergr

Product

Company

Legal